The current market landscape is defined by a shift toward dispersion as investors navigate the intersection of Federal Reserve policy, AI-driven earnings, and credit market volatility. While the Fed’s recent balanced tone provided a rare sigh of relief for equity markets, the focus has pivoted toward the sustainability of AI demand and the intensifying competitive pressures facing mega-cap tech companies. Retail investor participation has cooled, evidenced by a 20% decline in volume since June, leading to a more two-sided options market where put buying has increased. Amidst this consolidation, credit markets face supply-demand imbalances, with 2026 issuance significantly outpacing 2025 levels. Biotech emerges as a compelling opportunity, offering secular growth potential bolstered by the prospect of lower interest rates, increased M&A activity, and the integration of AI in drug discovery.
Sign in to continue reading, translating and more.
Open full episode in Podwise